Maxime Dewolf

487 total citations
27 papers, 181 citations indexed

About

Maxime Dewolf is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Physiology. According to data from OpenAlex, Maxime Dewolf has authored 27 papers receiving a total of 181 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 4 papers in Physiology. Recurrent topics in Maxime Dewolf's work include Lung Cancer Treatments and Mutations (7 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Maxime Dewolf is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Maxime Dewolf collaborates with scholars based in France, Belgium and Austria. Maxime Dewolf's co-authors include Gaëtan Deslée, Julien Ancel, Jeanne‐Marie Perotin, Valérian Dormoy, Myriam Polette, Véronique Dalstein, Béatrice Nawrocki‐Raby, Christine Gilles, Sandra Dury and Claire Launois and has published in prestigious journals such as Annals of Oncology, Frontiers in Immunology and The Journal of Pathology.

In The Last Decade

Maxime Dewolf

25 papers receiving 176 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maxime Dewolf France 9 91 67 46 29 27 27 181
Marco Sposito Italy 10 70 0.8× 129 1.9× 30 0.7× 20 0.7× 36 1.3× 38 233
Sam O. Kleeman United States 8 53 0.6× 49 0.7× 85 1.8× 48 1.7× 49 1.8× 13 216
Hazel Lote United Kingdom 8 78 0.9× 116 1.7× 37 0.8× 22 0.8× 6 0.2× 17 198
Marcus Matsushita Brazil 7 38 0.4× 85 1.3× 49 1.1× 38 1.3× 9 0.3× 12 179
Koichi Takayama Japan 6 33 0.4× 58 0.9× 39 0.8× 31 1.1× 67 2.5× 18 166
Tamara Saurí Spain 9 45 0.5× 107 1.6× 65 1.4× 41 1.4× 19 0.7× 30 226
Antonio García‐Escudero Spain 9 78 0.9× 36 0.5× 69 1.5× 35 1.2× 23 0.9× 21 223
Stuart Cramer United States 7 32 0.4× 55 0.8× 28 0.6× 11 0.4× 14 0.5× 12 151
Vladimír Frýba Czechia 7 26 0.3× 40 0.6× 51 1.1× 28 1.0× 25 0.9× 12 177
Claire Edgerly United States 7 86 0.9× 57 0.9× 66 1.4× 18 0.6× 30 1.1× 17 185

Countries citing papers authored by Maxime Dewolf

Since Specialization
Citations

This map shows the geographic impact of Maxime Dewolf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maxime Dewolf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maxime Dewolf more than expected).

Fields of papers citing papers by Maxime Dewolf

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maxime Dewolf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maxime Dewolf. The network helps show where Maxime Dewolf may publish in the future.

Co-authorship network of co-authors of Maxime Dewolf

This figure shows the co-authorship network connecting the top 25 collaborators of Maxime Dewolf. A scholar is included among the top collaborators of Maxime Dewolf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maxime Dewolf. Maxime Dewolf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Dewolf, Maxime, Véronique Dalstein, A. Durlach, et al.. (2025). Comparing neutrophil-to-lymphocyte ratio (NLR), absolute neutrophil count (ANC) and derived NLR as predictive biomarkers in first-line immunotherapy for non-small cell lung cancer: a retrospective study. Translational Lung Cancer Research. 14(4). 1212–1230. 1 indexed citations
4.
Ancel, Julien, Valérian Dormoy, Béatrice Nawrocki‐Raby, et al.. (2023). Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors. Frontiers in Immunology. 14. 1171649–1171649. 16 indexed citations
5.
6.
Perotin, Jeanne‐Marie, Fabien Gierski, L. Bolko, et al.. (2022). Cluster analysis unveils a severe persistent respiratory impairment phenotype 3-months after severe COVID-19. Respiratory Research. 23(1). 199–199. 2 indexed citations
7.
Slimano, Florian, Amélie Cransac, Pascal Foucher, et al.. (2022). Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: The prospective IPPEM study. Lung Cancer. 166. 114–121. 4 indexed citations
8.
Ancel, Julien, Jeanne‐Marie Perotin, Arnaud Bonnomet, et al.. (2021). Impaired Ciliary Beat Frequency and Ciliogenesis Alteration during Airway Epithelial Cell Differentiation in COPD. Diagnostics. 11(9). 1579–1579. 12 indexed citations
9.
Perotin, Jeanne‐Marie, et al.. (2021). Bronchoscopic management of asthma, COPD and emphysema. European Respiratory Review. 30(159). 200029–200029. 5 indexed citations
10.
Ancel, Julien, Jeanne‐Marie Perotin, Maxime Dewolf, et al.. (2021). Hypoxia in Lung Cancer Management: A Translational Approach. Cancers. 13(14). 3421–3421. 25 indexed citations
11.
Mongaret, Céline, et al.. (2021). Safety and Survival Outcomes in Lung Cancer Patients Receiving Carboplatin: Impact of Uncapped Dosage. Chemotherapy. 66(3). 72–77. 2 indexed citations
12.
Ancel, Julien, Jeanne‐Marie Perotin, Sandra Dury, et al.. (2020). Sonic hedgehog signalling as a potential endobronchial biomarker in COPD. Respiratory Research. 21(1). 207–207. 14 indexed citations
13.
Ancel, Julien, et al.. (2020). Hémangiomatose multifocale bronchique, ganglionnaire, splénique et osseuse. Revue des Maladies Respiratoires. 37(3). 275–279. 3 indexed citations
14.
Ancel, Julien, Véronique Dalstein, Gonzague Delépine, et al.. (2020). FHITlow/pHER2high signature in non‐small cell lung cancer is predictive of anti‐HER2 molecule efficacy. The Journal of Pathology. 251(2). 187–199. 10 indexed citations
15.
Ancel, Julien, Maxime Dewolf, Gaëtan Deslée, et al.. (2020). Clinical Impact of the Epithelial-Mesenchymal Transition in Lung Cancer as a Biomarker Assisting in Therapeutic Decisions. Cells Tissues Organs. 211(2). 91–109. 13 indexed citations
16.
Dormoy, Valérian, Maxime Dewolf, Sandra Dury, et al.. (2019). Asthme et obésité : mécanismes et pistes thérapeutiques. Revue des Maladies Respiratoires. 37(2). 134–143. 6 indexed citations
17.
Perotin, Jeanne‐Marie, Claire Launois, Maxime Dewolf, et al.. (2018). Managing patients with chronic cough: challenges and solutions. Therapeutics and Clinical Risk Management. Volume 14. 1041–1051. 17 indexed citations
18.
Launois, Claire, Sandra Dury, Frédéric Sailhan, et al.. (2018). Hereditary multiple exostoses of the ribs as an uncommon cause of pneumothorax. Medicine. 97(35). e11894–e11894. 8 indexed citations
19.
Gobert, Aurélien, Marianne Veyri, A. Lavolé, et al.. (2018). Tolerance and efficacy of immune-checkpoint inhibitors for cancer in people living with HIV (PWHIV). Annals of Oncology. 29. viii733–viii733. 3 indexed citations
20.
Dewolf, Maxime, et al.. (2017). Efficacité de l’erlotinib en réanimation chez les patients présentant un cancer bronchique non à petites cellules avec une mutation de l’EGFR. Revue de Pneumologie Clinique. 73(3). 135–139. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marco Sposito Breakdown of academic impact, for papers by Sam O. Kleeman Breakdown of academic impact, for papers by Hazel Lote Breakdown of academic impact, for papers by Marcus Matsushita Breakdown of academic impact, for papers by Koichi Takayama Breakdown of academic impact, for papers by Tamara Saurí Breakdown of academic impact, for papers by Antonio García‐Escudero Breakdown of academic impact, for papers by Stuart Cramer Breakdown of academic impact, for papers by Vladimír Frýba Breakdown of academic impact, for papers by Claire Edgerly
Rankless by CCL
2026